Outcomes of a placebo run-in period in a head and neck cancer chemoprevention trial

Controlled Clinical Trials

Volumn 18, Issue 3, 1997, Pages 228-240

  Hudmon, Karen Suchanek ^a   Chamberlain, Robert M ^a   Frankowski, Ralph F ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adherence; Cancer chemoprevention; Clinical trials; Compliance; Prevention trials; Run in

Indexed keywords

ISOTRETINOIN; PLACEBO;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDUCATION; ETHNOLOGY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PILL; PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ANTICARCINOGENIC AGENTS; BIAS (EPIDEMIOLOGY); CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; ISOTRETINOIN; NEOPLASMS, SECOND PRIMARY; PATIENT DROPOUTS; TREATMENT OUTCOME;

EID: 0343487825     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(97)00004-4     Document Type: Article

References (33)

1. DeMets DL, Newcomb PA, Carey P. Design issues for a breast cancer chemoprevention trial. Prev Med 1991;20:101-108.
2. Palta M, McHugh R. Planning the size of a cohort study in the presence of both losses to follow-up and noncompliance. J Chron Dis 1980;33:501-512.
3. Probstfield JL. Clinical trial prerandomization compliance (adherence) screen. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press, Ltd; 1994:323-333.
4. Freedman LS. The effect of partial noncompliance on the power of a clinical trial. Controlled Clin Trials 1990;11:157-168.
5. Lang JM. The use of a run-in to enhance compliance. Stat Med 1990;9:87-95.
6. Leventhal H, Nerenz DR, Leventhal EA, Love RR, Bendena LM. The behavioral dynamics of clinical trials. Prev Med 1991;20:132-146.
7. Friedman LM, Furberg C, DeMets DL. Fundamentals of Clinical Trials. St. Louis: Mosby-Year Book, Inc; 1996.
8. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-519.
9. Schork MA, Remington RD. The determination of sample size in treatment-control comparisons for chronic disease studies in which drop-out or nonadherence is a problem. J Chron Dis 1967;20:233-239.
10. Insull W, Russell ML. Adherence management in long-term clinical trials for prevention. J Nutr, Growth and Cancer 1987;4:29-35.
11. Probstfield JL, Russell ML, Insull W, Yusuf S. Dropouts from a clinical trial, their recovery and characterization: a basis for dropout management and prevention. In: Shumaker SA, Schron EB, Ockene JK, eds. The Handbook of Health Behavior Change. New York: Springer; 1990:376-400.
12. Probstfield JL, Russell ML, Henske JC, Reardon RJ, Insull W. Successful program for recovery of dropouts to a clinical trial. Am J Med 1986;80:777-784.
13. Moon TE. Planning the analysis of a breast cancer prevention trial. Prev Med 1991;20:109-118.
14. Engstrom PF. Specific compliance issues in an antiestrogen trial of women at risk for breast cancer. Prev Med 1991;20:125-131.
15. Buring JE, Hennekens CH. Current issues in cancer chemoprevention. In: Hakama M, Beral V, Cullen JW, Parkin DM, eds. Evaluating Effectiveness of Primary Prevention of Cancer. Lyons, France: IARC;1990:185-193.
16. Buring JE, Hennekens CH. Methological issues in the design of primary prevention trials. In: Anderson PN, Engstrom PF, Mortenson LE, eds. Advances in Cancer Control: Innovations and Research. New York: Alan R. Liss; 1989:41-49.
17. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313-316.
18. Knipschild P, Leffers P, Feinstein AR. The qualification period. J Clin Epidemiol 1991;44:461-464.
19. Davis CE, Applegate WB, Gordon DJ, Curtis RC, McCormick M. An empirical evaluation of the placebo run-in. Controlled Clin Trials 1995;16:41-50.
20. Moon TE, Levine N, Cartmel B, et al, and the Southwest Skin Cancer Prevention Study Group. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. Cancer Epidemiol Biomarkers and Prev 1995;4:661-669.
21. Jones EE, Sigall H. The bogus pipeline: a new paradigm for measuring affect and attitude. Psychol Bull 1971;76:349-364.
22. Armitage P, Berry G. Statistical Methods in Medical Research. Boston: Blackwell Scientific Publications; 1994.
23. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions, and measuring and reducing errors. Stat Med 1996;15;361-387.
24. SAS Institute Inc. Regression Examples Using the SASR System, Version 6, First Logistic Edition. Cary, NC: SAS Institute Inc. 1995.
25. Moon TE. Study design for the prevention of aerodigestive tract cancers. In: Newell GR, Hong WK, eds. The Biology and Prevention of Aerodigestive Tract Cancers. New York: Plenum Press; 1992:105-109.
26. Tijssen JGP, Lubsen J. Are (placebo) run-in periods necessary in a drug trial in a chronic disorder? Controlled Clin Trials 1989;10:334 (Abstract).
27. Li J, Taylor PR, Li G, Blot WJ, Yu Y, Ershow AG, Sun Y, Yang CS, Yang Q, Tangrea JA, Zheng S, Greenwald P, Cahill J. Intervention studies in Linxian, China - an update. J Nutr, Growth and Cancer 1986;3:199-206.
28. Omenn GS, Goodman GE, Thornquist MD, Rosenstock L, Barnhart S, Gylys-Colwell I, Metch B, Lund B. The carotene and retinol efficacy trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers. Cancer Epidemiol Biomarkers and Prev 1993;2:381-387.
29. Greenberg ER, Baron JA, Stevens MM, Stunkel TA, Mandel JS, Spencer SK, Elias PM, Lowe N, Nierenberg DN, Bayrd G, Vance JC. The skin cancer prevention study: design of a clinical trial of beta-carotene among persons at high risk for nonmelanoma skin cancer. Controlled Clin Trials 1989;10:153-166.
30. Albanes D, Virtamo J, Rautalahti M, Pikkarainen J, Taylor PR, Greenwald P, Heinonen OP. Pilot study: the U.S.-Finland lung cancer prevention trial. J Nutr, Growth and Cancer 1986;3:207-214.
31. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD. Beta-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995;62:1431S-1438S.
32. Cramer JA. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991.
33. Hudmon KS, Kinney AK. Issues of enrollment bias in cancer chemoprevention trials. Cancer Bull 1995;47:339-342.